Chronic Leukemias

Chronic Leukemias

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.

No Survival Benefit With Adding Rituximab to Ibrutinib in Patients With Chronic Lymphocytic Leukemia

In a randomized, open-label, single-center, phase II study, researchers found that the addition of rituximab to ibrutinib did not improve progression-free survival (PFS; primary...

FDA Expands Approval of Dasatinib for Pediatric Patients With CP-CML

The U.S. Food and Drug Administration expanded the indication of the tyrosine kinase inhibitor dasatinib to include pediatric patients with Philadelphia chromosome–positive (Ph+) chronic-phase...
How I Treat In Brief

How I Treat In Brief: Atypical Chronic Myeloid Leukemia

This month, Jason Gotlib, MD, discusses the diagnosis and treatment of patients with atypical chronic myeloid leukemia. This material was repurposed from “How I Treat...

Selinexor Induces Response in Patients With Various Subtypes of Non-Hodgkin Lymphoma and Chronic Lymphocytic...

The heterogeneity of the various subtypes of non-Hodgkin lymphomas (NHLs) necessitates the development of specific therapies that address fundamental mechanisms that are dysregulated in...
On location

BFORE Trial: Bosutinib Could Be a “Welcome” New Treatment Option for Chronic-Phase CML

Treatment with the dual SRC/ABL tyrosine kinase inhibitor bosutinib was associated with a higher major molecular response (MMR), deeper response, and shorter time to...
stem cell

Ponatinib Increased Overall Survival in Patients with Chronic-Phase CML

A study published in Cancer found that treatment with ponatinib significantly improved overall survival (OS) for patients with chronic-phase chronic myeloid leukemia (CP-CML) and...

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.